A5038198845- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- RNA Research and Splicing
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Pancreatic and Hepatic Oncology Research
- Neuroblastoma Research and Treatments
- Head and Neck Cancer Studies
- Bone health and treatments
- Bone and Joint Diseases
- Occupational and environmental lung diseases
- Sarcoma Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- CAR-T cell therapy research
- Pluripotent Stem Cells Research
- Cancer-related molecular mechanisms research
- Ethics in Clinical Research
- Genomics and Chromatin Dynamics
- Blood disorders and treatments
Essen University Hospital
2015-2024
Jena University Hospital
2024
University of Duisburg-Essen
2012-2019
University Hospital Leipzig
2014
Medizinische Hochschule Hannover
2011-2014
Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in recent decades. However, it remained unknown whether advances first-line treatment, supportive care, or second-line therapy mainly contributed to this improvement. Here, we retrospectively analyzed outcome and clinical data 1940 AML (younger than 18 years age), enrolled the population-based AML-BFM trials between 1987 2012. While 5-year probability OS (pOS) from 49 ± 3% (1987–1992) 76 4% (2010–2012; p...
Although regulation of stem cell homeostasis by microRNAs (miRNAs) is well studied, it unclear how individual miRNAs genomically encoded within an organized polycistron can interact to induce integrated phenotype. miR-99a/100, let-7 , and miR-125b paralogs are in two tricistrons on human chromosomes 11 21. They highly expressed hematopoietic cells (HSCs) acute megakaryoblastic leukemia (AMKL), aggressive form with poor prognosis. Here, we show that miR-99a/100∼125b transcribed as a...
BACKGROUND To obtain better insight into the biology of acute myeloid leukemia (AML) in various age groups, this study focused on genetic changes occurring during a lifetime. METHODS This analyzed relation between and genetics from birth to 100 years 5564 patients with de novo AML diagnosed 1998 2012 (1192 nationwide pediatric studies [AML Berlin‐Frankfurt‐Münster 98 2004] 4372 adults registered Munich Leukemia Laboratory). RESULTS The frequencies cytogenetic subgroups were age‐dependent....
A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood
Key Points A case of MLL-rearranged leukemia that rapidly adapts to immunological stimuli illustrating the high plasticity this phenotype.
Despite recent advances in the treatment of children with acute megakaryoblastic leukemia (AMKL) using intensified protocols, clear prognostic indicators, and recommendations for this myeloid (AML) subgroup are yet to be defined. Here, we report outcome 97 pediatric patients de novo AMKL (excluding Down syndrome [DS]) enrolled prospective multicenter studies AML-BFM 98 04 (1998-2014). occurred 7.4 % AML cases, at younger age (median 1.44 years) lower white blood cell count (mean 16.5 ×...
Acute myeloid leukemia is a life-threatening malignancy in children and adolescents treated predominantly by risk-adapted intensive chemotherapy that partly supported allogeneic stem cell transplantation. Mutations the WT1 gene NUP98-NSD1 fusion are predictors of poor survival outcome/prognosis frequently occur combination with internal tandem duplications juxta-membrane domain FLT3 (FLT3-ITD). To re-evaluate effect these factors contemporary protocols, 353 patients (<18 years) Germany...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse independent cooperative group studies conducted by COG the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of last I-BFM trial until 2017, while 852 on Phase 3 trials (AAML0531, AAML1031). Overall at 5 years (OS) was 42 ± 4% (BFM) 35 2% (COG). Initial high-risk features (BFM 32...
Abstract A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study 1256 children with KMT2A-r AML aims to validate prognostic value established recurring KMT2A fusions and additional aberrations (ACAs) define additional, ACAs, evaluating their relevance. Compared our previous study, 3 groups were...
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies, and identified 76 (
The international pediatric oncology community has a long history of research collaboration. In the United States, 2019 launch Children's Cancer Data Initiative puts focus on developing rich and robust data ecosystem for oncology. this spirit, we present here our experience in constructing Pediatric Commons (PCDC) to highlight significance effort fighting cancer improving outcomes provide essential information those creating resources other disease areas. University Chicago's PCDC team...
Survival in children with relapsed/refractory acute myeloid leukemia is unsatisfactory. Treatment consists of one course fludarabine, cytarabine and liposomal daunorubicin, followed by fludarabine stem-cell transplantation. Study ITCC 020/I-BFM 2009-02 aimed to identify the recommended phase II dose clofarabine replacing abovementioned combination regimen (3+3 design). Escalating levels (20-40 mg/m2/day × 5 days) daunorubicin (40-80 mg/m2/day) were administered (2 g/m2/day days). Liposomal...
Successful management of relapse is critical to improve outcomes children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second AML. Among 1222 pediatric patients the population-based AML-Berlin–Frankfurt–Munster (BFM) study group (2004 until 2017), 73 met quality parameters for inclusion in this study. Central review source documentation warranted accuracy reported data. Treatment approaches included palliation 17 (23%), intensive therapy...
We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-Frankfurt-Münster (BFM) 04 protocol to determine prognostic value specific chromosomal aberrations including monosomal (MK+), complex (CK+) and hypodiploid (HK+) karyotypes, individually in combination. Multivariate regression identified particular MK+ (n=22) as new independent risk factor for poor event-free survival (EFS 23±9% vs 53±2% all other patients, P=0.0003), even...
Reprogramming of somatic cells into patient-specific pluripotent analogues human embryonic stem (ESCs) emerges as a prospective therapeutic angle in molecular medicine and tool for basic cell biology. However, the combination relative inefficiency high variability non-defined culture conditions precluded use this technique clinical setting impeded comparability between laboratories. To overcome these obstacles, we sequentially devised reprogramming protocol using one lentiviral-based...
Abstract Children with Down syndrome are at a high risk of developing transient abnormal myelopoiesis (TAM; synonym: TMD) or myeloid leukemia (ML-DS). While most patients TAM asymptomatic and go into spontaneous remission without need for therapy, around 20% die within the first six months due to TAM-related complications. Another 20–30% progress from ML-DS. ML-DS particularly vulnerable therapy-associated toxicity, but prognosis relapsed is extremely poor – thus, therapy schemata must...
Aberrant activation of key signaling-molecules is a hallmark acute myeloid leukemia (AML) and may have prognostic therapeutic implications. AML summarizes several disease entities with variety genetic subtypes. A comprehensive model spanning from signal patterns in major subtypes pediatric (pedAML) to outcome prediction pre-clinical response signaling inhibitors has not yet been provided. We established high-throughput flow-cytometry based method assess phospho-proteins (phospho-flow) 166...